Tag Archives: mdvn

Biotech Medivation (MDVN) jumped to a new high in the stock market today after its Q3 results beat estimates late Thursday on strong sales of cancer drug Xtandi. Medivation’s earnings totaled 96 cents a share, reversing a year-earlier loss and beating analysts’ consensus by 13 cents, according to Thomson Reuters. Revenue soared 234% to $200.5 million, topping consensus by nearly $19 million. The company didn’t formally change guidance, but said

Medivation (MDVN) stock rose to a five-month high Friday after the biotech company soundly beat Q2 estimates late Thursday and turned the corner to profitability. Medivation stock was up nearly 11.5% in morning trading on the stock market today, near 84 and within hailing distance of its all-time high of 88.20, touched on Feb. 25. Medivation reported a profit of 60 cents a share, reversing a year-earlier loss and more than doubling analysts’